KEAP1 and lung adenocarcinoma: In our study, although a significant association between the gene status and treatment response of any of the evaluated patients was not observed, KEAP1 mutation contributed to an inferior OS, which supported the findings of a previous report indicating that KEAP1 mutation is a prognostic factor for patients with lung adenocarcinoma receiving ICIs.